Teladoc Health Files 8-K on Operations and Personnel
Ticker: TDOC · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1477449
| Field | Detail |
|---|---|
| Company | Teladoc Health, Inc. (TDOC) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-events, financial-reporting, personnel-changes
Related Tickers: TDOC
TL;DR
TDOC filed an 8-K on Oct 23rd covering Oct 17th events - ops, exec changes, and financials.
AI Summary
Teladoc Health, Inc. filed an 8-K on October 23, 2025, reporting events as of October 17, 2025. The filing covers results of operations, financial condition, departure/election of directors and officers, and includes a Regulation FD disclosure and financial exhibits. Specific financial figures or operational details were not provided in this excerpt.
Why It Matters
This 8-K filing indicates significant corporate events are being reported by Teladoc Health, Inc., which could impact investor understanding of the company's current status and future direction.
Risk Assessment
Risk Level: medium — The filing indicates potential changes in operations or leadership, which can introduce uncertainty and risk for investors.
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- October 17, 2025 (date) — Earliest event reported
- October 23, 2025 (date) — Filing date
FAQ
What specific results of operations or financial condition changes are being reported by Teladoc Health, Inc.?
The provided excerpt of the 8-K filing indicates that 'Results of Operations and Financial Condition' is an item being reported, but it does not detail the specific results or changes.
Were there any departures or elections of directors or officers on or around October 17, 2025?
Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of information being reported.
Does the filing include any compensatory arrangements for officers?
Yes, 'Compensatory Arrangements of Certain Officers' is listed as an item of information within the filing.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
A Regulation FD Disclosure item indicates that the company is providing information to the public in a manner that complies with Regulation Fair Disclosure, ensuring broad dissemination of material information.
Are financial statements and exhibits included with this 8-K filing?
Yes, 'Financial Statements and Exhibits' is listed as an item of information being filed.
Filing Stats: 1,345 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2025-10-23 16:07:40
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha
Filing Documents
- tdoc-20251017.htm (8-K) — 35KB
- exhibit9912.htm (EX-99.1) — 40KB
- 0001477449-25-000114.txt ( ) — 237KB
- tdoc-20251017.xsd (EX-101.SCH) — 2KB
- tdoc-20251017_def.xml (EX-101.DEF) — 15KB
- tdoc-20251017_lab.xml (EX-101.LAB) — 26KB
- tdoc-20251017_pre.xml (EX-101.PRE) — 16KB
- tdoc-20251017_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 23, 2025, Teladoc Health, Inc. (the "Company" or "we") issued a press release announcing preliminary results for the quarter ended September 30, 2025. These financial results are preliminary, unaudited and subject to change in connection with the completion of the Company's financial closing process and the preparation of its financial statements for the third quarter of 2025. In addition, the Company announced that it continues to expect its consolidated financial results for the year ending December 31, 2025 to be consistent with the outlook range disclosed in the Company's second quarter earnings release on July 29, 2025. The Company's outlook for segment-level results for the year ending December 31, 2025 is expected to be discussed further on the Company's previously announced conference call to review third quarter results on October 29, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. This press release contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1. The foregoing information (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 17, 2025, Ms. Mala Murthy, Chief Financial Officer of the Company, informed the Company of her decision to
01 Regulation FD
Item 7.01 Regulation FD. A copy of the press release regarding the matters discussed in Item 2.02 and Item 5.02 of this Current Report is furnished herewith as Exhibit 99.1. The information furnished under this Item 7.01 (including Exhibit 99.1) of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements This report contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members, BetterHelp paying users or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicat
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Teladoc Health, Inc. press release, dated October 23 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Furnished herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 23, 2025 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary